- RLMD reported a Q1 net loss of $0.22 per share, missing estimates.
- The result was $0.0211 below the consensus analyst forecast of -$0.1989.
- Quarterly revenue was $0, in line with analyst expectations.
Back
RLMD misses Q1 2026 EPS estimates by over 10 percent
Realm Therapeutics (RLMD) reported a first-quarter net loss of $0.22 per share for the period ending March 31, 2026, missing consensus estimates by more than 10 percent as the company recorded no revenue.
The result fell short of the analyst consensus estimate, which projected a loss of $0.1989 per share. The company reported no revenue for the quarter, which was in line with analyst expectations.
By the Numbers
The 10.6% earnings miss highlights the challenges for the pre-revenue company. Investors will now look for an update on the company's development pipeline and cash burn rate in the next shareholder communication.
This article is for informational purposes only and does not constitute investment advice.
